RVNC Overview
Upcoming Projects (RVNC)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RVNC)
-
A 2nd View: Looking at Evolus' DWP-450 (PrabotulinumtoxinA) purified botulinum toxin in treating glabellar (frown) lines
Tickers: EOLS, RVNC, AGN
Executed On: Oct 30, 2018 at 04:00 PM EDT -
Looking at Evolus' DWP-450 (PrabotulinumtoxinA) purified botulinum toxin in treating glabellar (frown) lines
Tickers: EOLS, RVNC, AGN
Executed On: Oct 23, 2018 at 06:30 PM EDT -
Exploring the market potential of Revance's RT002 botulinum toxin injectable for the treatment of glabellar (frown) lines
Tickers: RVNC, AGN, NESN.VX
Executed On: Jul 20, 2018 at 08:00 AM EDT -
Preparing for Revance Therapeutics’ Phase 3 pivotal trial data releases of RT002 botulinum toxin injectable for the treatment of glabellar (frown) lines in Q4 2017
Tickers: RVNC, AGN, NESN.VX
Executed On: Oct 27, 2017 at 01:00 PM EDT
Upcoming & Overdue Catalysts (RVNC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RVNC)
-
Revance's (RVNC) RT002 data from Pivotal SAKURA Phase 3 Trials for Glabellar Lines released
Ticker: RVNC
Occurred on: Dec 05, 2017 -
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
Ticker: RVNC
Occurred on: Jun 13, 2016 -
Phase 2 trial of RT001 for Hyperhidrosis to be completed 1Q 2016. Larger Phase 2 trial planned for 2016
Ticker: RVNC
Occurred on: Mar 02, 2016 -
Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines
Tickers: RVNC, PFE, VRX, AGN
Occurred on: Oct 29, 2015
Strategic Initiatives (RVNC)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
